Post Minimally Invasive Thorascopic Surgical Pain Clinical Trial
Official title:
The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade
Verified date | February 2015 |
Source | Cedars-Sinai Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the effect of the addition of dexamethasone to intraoperative intercostal nerve block bupivicaine solutions on the duration of pain relief and post operative pulmonary function.
Status | Unknown status |
Enrollment | 50 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - 18 - 80 years old of either gender, scheduled for unilateral VATS procedure with Dr. McKenna for resection of lung tumor. Exclusion Criteria: - ASA IV and above - Intolerance, allergy, or contraindication to use of any medications used in this study - Significant coronary artery disease (abnormal stress test, myocardial infarction within the last 3 months) - Uncontrolled hypertension (BP > 140/90) - History of prior ipsilateral thorascopic surgery - Cardiac arrhythmias particularly prolonged QT syndrome - Drugs known to cause prolonged qT: class IA antiarrhythmics (quinidine, procainamide, dysopyramide), class III antiarrhythmics (sotalol, dofetalide, ibutalide, amiodarone), haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic antidepressants - Individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis - Pregnant or lactating women - Morbid obesity (BMI > 40 kg/m2) AND/OR weight > 150 kg - Chronic renal failure ( creatinine > 2.0 mg/dL) - Liver failure e.g., active cirrhosis - Alcohol or substance abuse within in the past 3 months - Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics, mineralocorticoid use, laxatives) - Restrictive lung disease (pulmonary fibrosis, myasthenia gravis) or FEV1 or FEV less than 70% of predicted value. - Type 2 diabetes - Neuropathic pain - Chronic opioid consumption (>30mg oxycodone or greater per day) - Cahexia from any cause - systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to surgery |
Country | Name | City | State |
---|---|---|---|
United States | Cedars Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Cedars-Sinai Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post operative pain | Patients will be evaluated for post operative pain using the NRS pain evaulation | 72 hours post operatively |